Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Open accessThe DOI matches its Crossref record; 131 of the 136 references it cites were found in a registry or an index.
Abstract
Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the crucial component of response to irinotecan. Furthermore, new formulations of the drug are introduced in order to better deliver the drug and avoid potentially life-threatening side effects. Here, we give a comprehensive overview on irinotecan’s molecular mode of action, metabolism, pharmacogenetics, and toxicity. Moreover, this article features clinically used combinations of the drug with other anticancer agents and introduces novel formulations of drugs (e.g., liposomal formulations, dendrimers, and nanoparticles). It also outlines crucial mechanisms of tumor cells’ resistance to the active metabolite, ethyl-10-hydroxy-camptothecin (SN-38). We are sure that the article will constitute an important source of information for both new researchers in the field of irinotecan chemotherapy and professionals or clinicians who are interested in the topic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Mechanisms of action for human topoisomerases. (A) Topoisomerase IA binds to DNA at a particular binding site, and then claves one strand, forming a transient 5′-phosphotyrosyl bond. The other DNA strand is transferred through the resultant break, allowing DNA to relax. Religation ends the process. (B) Toposiomerase IB works in a controlled rotation mechanism and in contrast to type IA enzymes forms a 3′-phosphotyrosyl bond with a DNA molecule. Both type I (A&B) topoisomerases do not require ATP hydrolysis as a source of energy. (C) Topoisomerase II binds to both ends of the DNA molecule, forms a double-strand break, and passes a segment of dsDNA through. This reaction is ATP-dependent [19].](https://figures.cochat.ai/paper-figures/7f178116e98944b58d61966403e83683/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-1.jpg)


![Figure 4 Mechanisms of cell death induced by irinotecan. The ternary irinotecan–topoisomerase I–nicked DNA complex with topoisomerase I (Topo I) inhibitor (SN-38) disables religation of the nicked strand and prevents topoisomerase release. Collision of the formed complex with advancing replication forks results in the formation of double-strand breaks (DSBs). This is followed by DNA damage response (DDR) signaling and TP53-induced gene expression of pro-apoptotic genes such as apoptosis regulator (BAX), phorbol-12-myristate-13-acetate-induced protein 1 (NOXA), or p53 up-regulated modulator of apoptosis (PUMA). Furthermore, down-regulation of the Bcl-2-like protein 1 isoform protein (BCL-xL) protein allows BAX and Bcl-2 homologous antagonist (BAK) embedding into the mitochondrial membrane and the formation of pores that allow the release of cytochrome C (cytC) from mitochondria and the subsequent formation of apoptosome with apoptotic protease-activating factor 1 (APAF-1) protein and procaspase-9. The activation of procaspase to caspase 9 (Casp-9) results in proteolytic cleavage and the conversion of procaspase 3 into active caspase 3 (Casp-3), which executes apoptosis [37,38,44,49,51].](https://figures.cochat.ai/paper-figures/e0271a41931a4560ab503b6a9b0123a1/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-4.jpg)
![Figure 5 Overview of irinotecan metabolism. CPT-11 is a prodrug that is converted to active metabolite ethyl-10-hydroxy-camptothecin (SN-38) by liver carboxylesterase converting enzymes (CES1/2) and is then transported to the liver by 1B1 polypeptide (OATP1B1) and inactivated by microsomal uridine 5′-diphospho-glucuronosyltransferase enzymes (UGTs): UGT1A1 and UGT1A9. Irinotecan is transported to bile by a group of the ATP-binding cassette transporters (ABC transporters): ABCB1, ABCC1, ABCC2, and ABCG2. Irinotecan is efficiently metabolized by cytochrome P450 enzymes: CYP3A4 and CYP3A5. This results in the generation of less active metabolites APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin) and NPC (7-ethyl-10-[4-amino-1-piperidino] carbonyloxycamptothecin). NPC (but not APC) can be further converted to SN-38 by CES1, and CES2 gut microbiota may also participate in irinotecan metabolism by the production of β-glucuronidase, which catalyzes the breakdown of SN-38G to SN-38. The inhibition of topoisomerase I (TOP1) results in DNA damage, replication fork arrest, and apoptotic cell death [53,54,55,56,57,58,59,60,61,62].](https://figures.cochat.ai/paper-figures/5036a4be7c55479baa6b8b63ea3ebd23/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Irinotecan (IRI) is a chemotherapeutic agent that inhibits topoisomerase I activity, which in turn inhibits both DNA replication and transcription49.”
From A statistical framework for high-content phenotypic profiling using cellular feature distributions (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredIn the citing paper
“Irinotecan exerts a cytotoxic effect by inhibiting DNA replication and transcription by targeting topoisomerase 1 (TOP-1) [87].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
DNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Self-citationVauthey, J.-N., Pawlik, T. M., Ribero, D., Wu, T.-T., Zorzi, D., Hoff, P. M., Xiong, H. Q., Eng, C., Lauwers, G. Y., Mino-Kenudson, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3074 · Cited by 1,300
Cited by
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
“Supercoiled DNA emerging during the above-mentioned processes can unwind and efficiently function as a template upon the introduction of single- or double-strand breaks (SSBs or DSBs) by topoisomerase type I and II enzymes, respectively [67].”
BackgroundSelf-citationStatus and Challenges of Plant-Anticancer Compounds in Cancer Treatment
Garcia-Oliveira, P., Otero, P., Pereira, A. G., Chamorro, F., Carpena, M., Echave, J., Fraga-Corral, M., Simal-Gandara, J., & Prieto, M. A. (2021) · Pharmaceuticals · doi:10.3390/ph14020157 · Cited by 303
“These issues could be solved by new drug formulations containing nanoparticles, polymer conjugates, dendrimers, peptides, and carbohydrates [64].”
BackgroundPEGylated therapeutics in the clinic
Gao, Y., Joshi, M., Zhao, Z., & Mitragotri, S. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10600 · Cited by 233
“124,125 The need for PEGylation of traditionally considered small molecule drugs is pressing, given that many effective small molecule drugs, such as irinotecan, 126 suffer from undesirable pharmacokinetic profiles.”
BackgroundTreatment for liver cancer: From sorafenib to natural products
Man, S., Luo, C., Yan, M., Zhao, G., Ma, L., & Gao, W. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113690 · Cited by 177
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Metadata
- Authors
- Kciuk, M., Marciniak, B., & Kontek, R.
- Affiliations
- University of Łódź (PL)
- Corresponding author
- Kciuk, Mateusz
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-07-12
- Volume
- 21
- Issue
- 14
- Pages
- 4919
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7404108
- OpenAlex
- W3041813955
- Cited by
- 266
- References
- 136
- Citations by year
- 2026: 29 · 2025: 76 · 2024: 66 · 2023: 50 · 2022: 29 · 2021: 13 · 2020: 3
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, camptothecin, SN-38, pharmacogenetics, drug metabolism, drug toxicity, combination chemotherapy, liposomal formulation, dendrimers, nanoparticles, drug resistance, anticancer agents
- MeSH terms
- Irinotecan, Antineoplastic Combined Chemotherapy Protocols, DNA, Neoplasm, Dosage Forms, Drug Compounding, Drug Synergism, Female, Humans, Male, Models, Molecular, Neoplasm Proteins, Neoplasms, Nucleic Acid Conformation, Prodrugs, Protein Conformation, Molecular Structure, Drug Resistance, Neoplasm, Polymorphism, Single Nucleotide, Topoisomerase I Inhibitors, Activation, Metabolic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview. https://app.cochat.ai/papers/10.3390/ijms21144919
- The paper
- Kciuk, M., Marciniak, B., & Kontek, R. (2020). Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21144919
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.